surbinsertib   Click here for help

GtoPdb Ligand ID: 14635

Synonyms: example 100 [WO2024107393] | SGR-3515
Compound class: Synthetic organic
Comment: Surbinsertib is the INN for a serine/threonine kinase inhibitor, that was included in WHO INN Proposed List 135 (July 2026). There is a structure match in patent WO2024107393A1 (Schroedinger) that claims WEE1 inhibitors for antineoplastic activity [1]. In July 2026, Schroedinger had declared only one active WEE1 inhibitor in their development pipeline- SGR-3515, that is in fact a dual WEE1/PKMYT1 (Myt1) inhibitor. We predict that surbinsertib is the likely proposed INN for SGR-3515.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 105.87
Molecular weight 576.76
XLogP 2.09
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1(C)C[C@@H]2[C@](C)(CO1)C3=C(N=C(N=C3)NC4=CC=C(C=C4)N5CCN(C)CC5)N2C6=NC(=CC=C6)N=S(=O)(C)C
Isomeric SMILES C[C@]12COC(C[C@H]1N(C3=NC(=NC=C23)NC4=CC=C(C=C4)N5CCN(CC5)C)C6=CC=CC(=N6)N=S(=O)(C)C)(C)C
InChI InChI=1S/C30H40N8O2S/c1-29(2)18-24-30(3,20-40-29)23-19-31-28(32-21-10-12-22(13-11-21)37-16-14-36(4)15-17-37)34-27(23)38(24)26-9-7-8-25(33-26)35-41(5,6)39/h7-13,19,24H,14-18,20H2,1-6H3,(H,31,32,34)/t24-,30-/m1/s1
InChI Key SZRUXMHQEFKMJJ-AYWVHJORSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
SGR-3515 is a lead oncology candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06463340 Study of SGR-3515 In Participants With Advanced Solid Tumors. Phase 1 Interventional Schrödinger, Inc.